Compounds > rb 6145
Page last updated: 2024-12-07

rb 6145

Description

RB 6145: structure given in first source; prodrug to RSU 1069; PD 144872 is the R-enantiomer of RB 6145 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID125377
CHEMBL ID63754
SCHEMBL ID8855507
MeSH IDM0185823

Synonyms (18)

Synonym
alpha-(((2-bromoethyl)amino)methyl)-2-nitro-1h-imidazole-1-ethanol monohydrobromide
rb 6145
1h-imidazole-1-ethanol, alpha-(((2-bromoethyl)amino)methyl)-2-nitro-, monohydrobromide
CHEMBL63754
ci 1010
rb-6145
129448-97-1
alpha-(((2-bromoethyl)amino)methyl)-2-nitro-1h-imidazole-1-ethanol
SCHEMBL8855507
XPBJPGMCFKYBBV-UHFFFAOYSA-N
1-(2-nitro-1-imidazolyl)-3-(2-bromoethylamino)-2-propanol hydrobromide
rb6145
DTXSID90924105
1-[(2-bromoethyl)amino]-3-(2-nitro-1h-imidazol-1-yl)propan-2-ol--hydrogen bromide (1/1)
122178-49-8
1-(2-bromoethylamino)-3-(2-nitroimidazol-1-yl)propan-2-ol;hydrobromide
1h-imidazole-1-ethanol, alpha-[[(2-bromoethyl)amino]methyl]-2-nitro-, hydrobromide (1:1)
AKOS040747359

Research Excerpts

Overview

RB 6145 is a novel hypoxic cell sensitizer and cytotoxin. Contains both an essential bioreductive nitro group and a bromoethylamino substituent.

ExcerptReferenceRelevance
"RB 6145 is a novel hypoxic cell sensitizer and cytotoxin containing both an essential bioreductive nitro group and a bromoethylamino substituent designed to form an alkylating aziridine moiety under physiological conditions. "( Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
Binger, M; Workman, P, 1991)		1.94
"RB 6145 is a pro-drug of the hypoxic cell radiosensitizer RSU 1069 with reduced systemic toxicity. "( Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
Adams, GE; Bowler, J; Cole, S; Lorimore, SA; Nolan, J; Stratford, IJ; Wright, EG, 1991)		2

Pharmacokinetics

ExcerptReferenceRelevance
" Reasoning that this may lie in a more beneficial pharmacokinetic profile, we investigated the plasma pharmacokinetics, tissue distribution and metabolism of RB 6145 in mice using a specially developed reversed-phase HPLC technique."( Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
Binger, M; Workman, P, 1991)		0.69

Compound-Compound Interactions

ExcerptReferenceRelevance
"To compare the effect on the RIF-1 murine sarcoma of nine bioreductive agents from five different classes when used in combination with either photodynamic therapy or clamping."( Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ, 1994)		0.29
"RIF-1 tumors implanted intradermally in C3H mice were treated with either 50J photodynamic therapy or with 120 min clamping in combination with either misonidazole, pimonidazole, metronidazole, nimorazole, RB6145, RSU1069, SR4233, mitomycin-C, or RB90740."( Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ, 1994)		0.29
"RSU1069 produced the greatest anti-tumor activity in combination with both photodynamic therapy and clamping."( Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ, 1994)		0.29
"Of the bioreductive agents studied RSU1069, RB6145 and mitomycin-C showed the greatest anti-tumor response in combination with photodynamic therapy."( Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ, 1994)		0.29

Dosage Studied

ExcerptRelevanceReference
" and oral dosing and possibly contributed to the acute toxicity."( Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
Binger, M; Workman, P, 1991)		0.5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID232995Differential toxicity expressed as the ratio of C50 (air) to C50 (nitrogen)1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins.
AID47690Cytotoxicity in air (MMT assay).1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins.
AID26663Half-life at pH of 5.5-6.0 at 23 degree Centigrade1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activate
AID1651882Cytotoxicity against human A549 cells incubated for 52 hrs in oxic condition by sulforhodamine B assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
AID133778Maximum tolerated dose was determined for compound administered intraperitoneally in C3H/He mice1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activate
AID217027Concentration which reduced survival to 1% following incubation 3 hours with V79 mammalian cells under hypoxic (Cnitrogen) conditions1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activate
AID110683In vitro concentration of gamma-radiation to give an enhancement ratio of 1.6 in mice when compared to control V79.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID47691Cytotoxicity in nitrogen (MMT assay).1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins.
AID217026Concentration which reduced survival to 1% following incubation 3 hours with V79 mammalian cells under aerobic (Cair) conditions1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activate
AID216722Reduction of optical density by 50% compared to controls when assay was performed under nitrogen in Hypoxic V79 Cells.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID213953Reduction of optical density by 50% compared to controls when assay was performed under air in Hypoxic V79 Cells.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID47688Molar concentration required to give a sensitizer enhancement ratio of 1.6 in hypoxic CHO (V79) cells.1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins.
AID233560The ratio of C50(AIR) to that of C50(N2).1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID231786Ratio of concentration which reduced V79 cell survival to 1% under aerobic conditions to that of hypoxic conditions1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activate
AID112714The maximum factor by which the cells were sensitized to radiation in mice1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID1651884Ratio of GI50 for human A549 cells in oxic condition to GI50 for anoxic condition2020Journal of natural products, 04-24, Volume: 83, Issue:4
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
AID115159The maximum tolerated dose described as the highest single intraperitoneal dose which did not produce severe or persistent clinical signs or death of the adult non-tumor bearing mice within 24 hours.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID1651883Cytotoxicity against human A549 cells incubated for 4 hrs in anoxic condition followed by oxic exposure for 48 hrs by sulforhodamine B assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's27 (75.00)18.2507
2000's6 (16.67)29.6817
2010's2 (5.56)24.3611
2020's1 (2.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.11 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index13.88 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (15.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetic acid
Acetic Acid: Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed). acetic acid : A simple monocarboxylic acid containing two carbons.		1.9710monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent
etanidazole
Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.. etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.		1.9910C-nitro compound;
imidazoles;
monocarboxylic acid amide		alkylating agent;
antineoplastic agent;
prodrug;
radiosensitizing agent
lomustine
[no description available]		2.3920N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
ondansetron
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.		1.9810carbazoles
mitomycin
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.		1.9810mitomycinalkylating agent;
antineoplastic agent
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		1.9810arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
xanthenes
Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.		1.9910xanthene
aziridine
[no description available]		1.9710azacycloalkane;
aziridines;
saturated organic heteromonocyclic parent		alkylating agent
oxazoles
Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.		1.97101,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
thiazoles
[no description available]		2.01101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
azomycin
azomycin: RN given refers to parent cpd with specified locant; structure		6.4320C-nitro compound;
imidazoles		antitubercular agent
porfiromycin
Porfiromycin: Toxic antibiotic of the mitomycin group, obtained from MITOMYCIN and also from Streptomyces ardus and other species. It is proposed as an antineoplastic agent, with some antibiotic properties.		1.9810
d-alpha tocopherol
Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.		2.0110alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
misonidazole
Misonidazole: A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic.		5.84180
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		1.9710benzenes;
phenyl acetates
thiazolyl blue
thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.		2.0110organic bromide saltcolorimetric reagent;
dye
oxazolidin-2-one
Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.		1.9710carbamate ester;
oxazolidinone		metabolite
1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol
1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol: structure given in first source		5.89190
aluminum phthalocyanine
aluminum phthalocyanine: the aluminum phthalocyanine can be sulfonated to different degrees; see also record for aluminum tetrasulfophthalocyanine		1.9810organic molecular entity
vadimezan
vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.		1.9910monocarboxylic acid;
xanthones		antineoplastic agent
rb 88716
RB 88716: structure given in first source		1.9710
rb 7040
[no description available]		1.9710
4-(3-(2-nitro-1-imidazolyl)-propylamino)-7-chloroquinoline hydrochloride
4-(3-(2-nitro-1-imidazolyl)-propylamino)-7-chloroquinoline hydrochloride: structure in first source		2.0510
nitroarginine
Nitroarginine: An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6). N(gamma)-nitro-L-arginine : An L-arginine derivative that is L-arginine in which the terminal nitrogen of the guanidyl group is replaced by a nitro group.		2.6830guanidines;
L-arginine derivative;
N-nitro compound;
non-proteinogenic L-alpha-amino acid
fosbretabulin
[no description available]		2.2510stilbenoid
nsc 600032
combretastatin A-1: from Combretum caffrum; structure given in first source		2.2510
apaziquone
apaziquone: structure given in first source; RN given refers to (E)-isomer		1.9810indoles
perfosfamide
[no description available]		1.9810
combretastatin a-4 disodium phosphate
[no description available]		2.2510
tirapazamine
Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.		4.7190aromatic amine;
benzotriazines;
N-oxide		antibacterial agent;
antineoplastic agent;
apoptosis inducer
phosphorus radioisotopes
Phosphorus Radioisotopes: Unstable isotopes of phosphorus that decay or disintegrate emitting radiation. P atoms with atomic weights 28-34 except 31 are radioactive phosphorus isotopes.		1.9910
ConditionIndicatedRelationship StrengthStudiesTrials
EHS Tumor
[description not available]		03.5990
Experimental Neoplasms
[description not available]		03.8140
Breast Cancer
[description not available]		02.2510
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.2510
Cancer of Lung
[description not available]		02.0510
Metastase
[description not available]		02.4420
Sarcoma, Epithelioid
[description not available]		02.4120
Lung Neoplasms
Tumors or cancer of the LUNG.		02.0510
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.4420
Sarcoma
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.		02.4120
Benign Neoplasms, Brain
[description not available]		02.0110
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		02.0110
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		02.0110
Anoxemia
[description not available]		02.730
Angiogenesis, Pathologic
[description not available]		02.4120
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		02.730
Carcinoma, Anaplastic
[description not available]		02.420
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		02.420
Benign Neoplasms
[description not available]		03.5930
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.5930
Experimental Mammary Neoplasms
[description not available]		01.9910
Carcinoma, Epidermoid
[description not available]		01.9910
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		01.9910
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		01.9910
Fibrosarcoma
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)		02.0110
Cancer of Cervix
[description not available]		02.0110
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		02.0110
Emesis
[description not available]		01.9810
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		01.9810
chemdatabank.com